Communiqués Novavax, Inc.

Actions

NVAX

US6700024010

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
8,940 ^USD	+6,18%		+11,06%	+33,04%

19/08	Point marchés-Wall Street en léger rebond avec le repli des rendements obligataires	RE
19/08	Les contrats à terme sur les actions américaines se stabilisent après la chute de la tech ; les investisseurs se concentrent sur les tensions au Moyen-Orient	RE

Communiqués

06/08	Novavax: Q2 Earnings Snapshot	AQ
06/08	Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights	PR
30/07	Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026	PR
01/06	Novavax to Participate in 2026 Jefferies Global Healthcare Conference	PR
07/05	Novavax to Participate in BofA Securities 2026 Health Care Conference	PR
06/05	Novavax : Q1 Reports & Financials (nvax q1 2026 earnings presentation)	PU
06/05	Novavax: Q1 Earnings Snapshot	AQ
06/05	Novavax Reports First Quarter 2026 Financial Results and Operational Highlights	PR
29/04	Novavax to Report First Quarter 2026 Financial Results on May 6, 2026	PR
18/04	Novavax : Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study	PU
30/03	Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development	PR
26/02	Novavax to Participate in Upcoming Investor Conferences	PR
26/02	Novavax: Q4 Earnings Snapshot	AQ
26/02	Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	PR
19/02	Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	PR
20/01	Novavax Announces Entering into a License Agreement with Pfizer	PR
07/01	Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference	PR
12/11	Novavax to Participate in Jefferies London Healthcare Conference	PR
06/11	Novavax : Q3 Reports & Financials (nvax q3 25 earnings presentation)	PU
06/11	Novavax: Q3 Earnings Snapshot	AQ
06/11	Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights	PR
04/11	Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment	PR
30/10/25	Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025	PR
22/10/25	Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy	PR
07/10/25	Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment	PR